Product Images Metformin Hydrochloride

This table provides a summary of mean percent changes from the baseline in the major lipid variables at the final visit for a 24-week study. The study is done using Metformin Hydrochloride tablets of 500 mg, 1000mg, and 1500 mg. The variables in which changes were observed are total cholesterol, total triglycerides, LDL-cholesterol, and HDL-cholesterol. The results show that there was a slight change in total cholesterol at the final visit, while there was a significant increase in total triglycerides. LDL-cholesterol had decreased in all cases, and HDL-cholesterol had increased for the 500 mg dose but decreased for the 1500 mg dose. All patients were on metformin hydrochloride tablets of 500 mg twice at baseline.*

This is a summary table from a 24-week study that evaluated the mean changes from baseline in Hemoglobin Ay, Fasting Plasma Glucose, and Body Weight. The table presents data for patients on Metformin Hydrochloride Extended Release Tablets at varying doses and frequencies (500 mg twice daily, 1000 mg once daily, and 1500 mg once daily) and shows the mean changes at week 12 and final visit. The study involved 67 to 74 patients, and the baseline Hemoglobin Ay, Fasting Plasma Glucose, and Body Weight values are also provided for each group.*

The table provides a summary of the percentage change from baseline of major serum lipid variables at the final visit for 29-week studies of Metformin Hydrochloride tablets versus placebo and combined Metformin Hydrochloride tablets/Glyburide versus monotherapy. The variables include Total Cholesterol, Triglycerides, LDL-Cholesterol, and HDL-Cholesterol. The percentage change for each variable is listed under each medication or medication combination with reference to the baseline.*

This appears to be a label of a medicine bottle for Metformin HCI 500mg with instructions and information about the medicine. It provides information like the dosage, ingredients, lot, NDC, and expiration dates. It also includes a warning label to keep the medicine out of reach of children and information about reporting side effects to FDA. The label suggests that the medicine should be stored at a temperature between 59-86°F.*

This is a description of a pediatric study where the mean age of patients is 13.8 years with a range between 10 to 16 years. All patients were on diet therapy at the beginning of the study. The asterisk denotes that there was no statistical significance found.*

Table 2 displays a comparison between Metformin Hydrochloride tablets and a placebo treatment. The table summarizes the mean changes from baseline in fasting plasma glucose, Hemoglobin A, and body weight at the final visit of a 29-week study. The study included 145 patients receiving Metformin Hydrochloride and 141 patients receiving placebo. The results show that at the final visit, patients receiving Metformin showed a significant decrease in fasting plasma glucose and Hemoglobin A, while there was no significant change in body weight. However, these changes were not statistically significant. All patients received diet therapy at the baseline.*

This table compares the effectiveness of Metformin Hydrochloride Tablets versus placebo in pediatrics. The table shows the summary of mean changes in plasma glucose and body weight at the final visit. Metformin Hydrochloride Tablets showed a significant decrease in plasma glucose levels compared to placebo with a p-value of less than 0.001. There was also a slight increase in body weight compared to placebo, but it was not statistically significant.*

The table provides a comparison between the effect of Metformin Hydrochloride Tablets combined with Glyburide, and either Glyburide or Metformin Hydrochloride Tablets taken alone. The comparison is made in terms of the mean changes from baseline observed in fasting plasma glucose, Hemoglobin A1c, and body weight at the final visit of a 23-week study. The table shows the number of patients involved in each group, and the p-values of the statistical tests made to assess the significance of the observed differences between the groups. The text also mentions that all patients were taking 20 mg/day of Glyburide at baseline, and that some of the differences observed were not statistically significant.*

This is a summary of a comparison between combined Metformin Hydrochloride Tablets and Insulin and Placebo Insulin based on mean changes from baseline in Hemoglobin A1c and Daily Insulin Dose. The table presents the treatment difference between the two groups. Results show that the Metformin Hydrochloride Tablets/Insulin had a statistically significant difference for Hemoglobin A1c compared to Placebo Insulin. The insulin dose was not significant.*